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ABSTRACT
Purpose Tumor cells can be effectively inactivated by heating
mediated by magnetic nanoparticles. However, optimized
nanomaterials to supply thermal stress inside the tumor remain
to be identified. The present study investigates the therapeutic
effects of magnetic hyperthermia induced by superparamagnetic
iron oxide nanoparticles on breast (MDA-MB-231) and pancreatic
cancer (BxPC-3) xenografts in mice in vivo.
Methods Superparamagnetic iron oxide nanoparticles, synthe-
sized either via an aqueous (MF66; average core size 12 nm) or
an organic route (OD15; average core size 15 nm) are analyzed
in terms of their specific absorption rate (SAR), cell uptake and
their effectivity in in vivo hyperthermia treatment.
Results Exceptionally high SAR values ranging from 658±
53 W*gFe
−1 for OD15 up to 900±22 W*gFe
−1 for MF66 were
determined in an alternating magnetic field (AMF, H=15.4 kA*m−1
(19 mT), f=435 kHz). Conversion of SAR values into system-
independent intrinsic loss power (ILP, 6.4±0.5 nH*m2*kg−1
(OD15) and 8.7±0.2 nH*m2*kg−1 (MF66)) confirmed the mark-
edly high heating potential compared to recently published data.
Magnetic hyperthermia after intratumoral nanoparticle injection
results in dramatically reduced tumor volume in both cancer models,
although the applied temperature dosages measured as CEM43T90
(cumulative equivalent minutes at 43°C) are only between 1 and
24min. Histological analysis of magnetic hyperthermia treated tumor
tissue exhibit alterations in cell viability (apoptosis and necrosis) and
show a decreased cell proliferation.
Conclusions Concluding, the studied magnetic nanoparticles
lead to extensive cell death in human tumor xenografts and are
considered suitable platforms for future hyperthermic studies.
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ABBREVIATIONS
AMF Alternating magnetic field
CEM43 Cumulative equivalent minutes at 43°C
CEM43T90 Cumulative equivalent minutes at a
T90 temperature of 43°C
ILP Intrinsic loss power
MNP Magnetic nanoparticles
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tumor surface
INTRODUCTION
The treatment of tumors with heat has been proven to inhibit
malignant proliferation and stimulate tumor cell death (1,2).
Defined temperature regimes have been suggested to be nec-
essary to effectively kill tumor cells. Two key studies in the
mid-80s indicated that a thermal dose of 42°C for more than
one hour will cause necrosis and/or apoptosis of cancer cells
(3,4). It was shown that temperatures in the range between 39
and 42°C are effective for clinical hyperthermia (5,6) and that
whole body hyperthermia at 39–41°C could significantly de-
lay tumor growth in a xenotransplanted colon carcinoma
model in rats (7). Subsequent preclinical and clinical studies
however often suffered from difficulties to deliver therapeutic
temperatures to tumor tissue and monitor the achieved
temperatures, making it difficult to correlate the applied
thermal dose with the respective therapy outcome (6,8,9).
One reason for the, so far, non-satisfactory therapy outcomes
is due to the lack of adequate temperature deposition right in
the tumor tissue, particularly by utilization of whole body
hyperthermia or external heating sources, such as ultrasound,
microwave or infrared radiation (10). Increased side effects
like burns on healthy tissue are further reasons why the ben-
efits of hyperthermia have not been well established in the
clinical routine.
An important parameter for the success of hyperthermia
treatment is the intratumoral temperature distribution, which
is measured by T90 values and which describes the tempera-
ture achieved or exceeded in 90% of the tumor area, together
with the cumulative equivalent minutes at a T90 temperature
of 43°C (CEM43T90) (4) as a measure of the temperature
dose. In this context the temperature dose is a superior indi-
cator for the therapy outcome to the temperature alone (11).
In two important clinical trials, one in humans with superficial
tumors and one in canines with soft tissue sarcoma, 20–100
CEM43T90 resulted in a better clinical outcome than 0.1–5
CEM43T90 (12,13). However, in the majority of clinical
studies it became obvious that temperature dosages of 30–
60 min CEM43 higher than 43°C were rarely achievable (6).
In contrast, the development of superparamagnetic nano-
particles (MNP) opened the window to locally deliver into
tumor tissue therapeutic temperatures in the hyperthermic
range. After selective and local accumulation in the tumor
area, MNP act as heating sources when subjected to alternat-
ing magnetic fields. Hereto, heat loss mechanisms during
magnetization reversal lead to a local temperature rise which
can be controlled by modulating the field strength or frequen-
cy as well as the MNP structural features and mass.
The main advantage of MNP based targeting is the poten-
tial to localize the treatment right into the tumor area by a
selective activation of the heating process when applying an
alternating magnetic field. In this context, the heat power
generated by MNP is dependent on their specific absorption
rate (SAR) and the influence of the intracellular degradation
and aggregation on preserving SAR values.
Due to the suitable benefits of magnetic hyperthermia on
cancer treatment, we hypothesize that MNP with high SAR
values and carefully controlled temperature dosages can be
used to achieve efficient hyperthermia treatments in vivo com-
pared to other methods, where the heat is externally delivered
to the tumor.
Here, we sought to check this hypothesis using two subcu-
taneous xenograft models of breast and pancreatic cancer to
identify cell line specific differences in treatment response.
With the aim to assess the influence of physicochemical MNP
properties on the induction of intratumoral heating and the
resulting therapeutic effects we investigated the therapy out-
come in course of hyperthermia treatment with two dispersions
of superparamagnetic particles prepared by different strate-
gies, whose heating potential was analyzed in conjunction with
hyperthermia effects. Furthermore, we were seeking to identify
correlations between temperature distribution, temperature
dose and the tumor volume and corresponding histological
parameters to gain further insight into the complex process
of tumor therapy by magnetic hyperthermia.
MATERIALS AND METHODS
Synthesis of Nanoparticles
To obtain information on the differences in hyperthermic
properties of MNP resulting from different synthesis routes,
we have synthesized superparamagnetic iron oxide nanopar-
ticles by two different chemical routes: OD15 MNP via
organic route and MF66 MNP via aqueous route.
The synthesis of OD15 was done according to the protocol
of Salas et al. 2012 (14) starting with an iron oleate complex.
Iron(III)oleate was mixed under nitrogen with oleic acid in 1-
octadecene. The mixture was warmed up with a heating
mantle and initially stirred (100 rpm) until T=60°C. Then
stirring was stopped and the reaction heated to reflux (315°C)
in order to narrow the MNP size distribution, enhance crys-
talline MNP and consequently to improve their magneto-
thermal properties (14). After cooling to room temperature,
the mixture was washed with ethanol, centrifuged, and the
nanoparticles were magnetically separated. MF66 nanoparti-
cles were produced by means of the co-precipitation tech-
nique (15).
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The MNP were initially coated with oleic acid and dis-
persed in toluene and finally transferred to a solution of
dimercaptosuccinic acid (DMSA) in dimethyl sulfoxide
(DMSO). The coating with DMSA was followed by
resuspension in distilled water, pH adjustment and sterile
filtration (14). Nanoparticle size and shape were examined
by transmission electron microscopy (TEM; 200 keV
Microscope JEOL JEM 2000 FXII). The mean particle size
and distribution were evaluated by measuring at least 200
nanoparticles and fitting the data to a log-normal distribution.
The hydrodynamic diameter was determined via dynamic light
scattering (DLS) and expressed as the Z-average size (Zetasizer
Nano ZS, Malvern Instruments, Herrenberg, Germany) after
nanoparticle suspension in water. Additionally, ζ-potential of
the MNP was measured (Zetasizer Nano ZS, Malvern
Instruments, Herrenberg, Germany).
Specific Absorption Rate
The specific absorption rate (SAR) of the MNP was deter-
mined bymeasuring the temperature increase per unit of mass
of MNP dispersion (200 μl) under given alternating magnetic
field (AMF) conditions (H=15.4 kA*m−1, f=435 kHz). The
MNP dispersion temperature was measured by using a com-
mercial fiber optic temperature thermometer (TS5 &
FOTEMPMK-19, Optocon AG, Dresden, Germany) with
an experimental error of ±0.2°C.
The SAR values were determined by extracting the tem-
perature increase immediately after switching on the alternat-
ing magnetic field (AMF) (16). The SAR determination is
based on the equation:





where c is the specific heat capacity of theMNPdispersion, mF
the mass of the fluid, mP the mass of the nanoparticles and
ΔT/Δt the maximum value of the linear slope at initial times
after switching on the alternating magnetic field.
Tomodulate particle immobilization which inhibits Brownian
motion, as it occurs in tissue in vivo, MNP were dispersed in
agarose gels (1% w/v) and in polyvinylalcohol hydrogels (PVA,
10% w/v) according to Gleichmar et al. 2009 and Ohta et al.
2004 (17,18). The polymerization time for agarose gels was 24 h
at 8°C, at −20°C for hydrogels, respectively. The mass of the
nanoparticle suspensions in water, agarose and hydrogels were
determined right before the SAR measurements.
In order to compare heating efficiencies from measure-
ments carried out in different MNP, laboratories, field
strengths and frequencies, we have calculated the intrinsic loss
power (ILP) of the studied MNP. According to Kallumadil
et al. 2009, the ILP is a system-independent parameter, which
allows comparison between SAR values obtained under
different AC field strength and frequency conditions (19).




where H is the applied field strength and f the used frequency.
Assessing Nanoparticle Internalization into Cells
To visualize the internalization of the MNP into MDA-MB-
231 cells, 8,000 cells/well were seeded onto 8-well culture
slides (BD Biosciences, Bedford, MA, USA), cultured over-
night (37°C, 5% CO2) and afterwards incubated with 125 pg
Fe/cell of the respective MNP formulation (OD15, MF66) for
24 h. Non-internalized MNP were removed by washing the
cells three times with HBSS before fixation of cells with 4%
(w/v) formaldehyde (10 min at 4°C). After two additional
washing steps the iron was stained using the Prussian Blue
staining method. To this end, slides containing fixed MDA-
MB-231 cells were incubated in a 10% potassium ferrocya-
nide solution (Sigma-Aldrich, Steinheim, Germany) followed
by a mix of 20% hydrochloric acid (Sigma-Aldrich,
Steinheim, Germany) and 10% potassium ferrocyanide solu-
tion. Slides were covered with Faramount (DAKO, Glostrup,
Denmark). Furthermore, to investigate thermosensitivity of
MDA-MB-231 and BxPC-3 cells, cell viability with and with-
out hyperthermia treatment was tested using the AlamarBlue
assay (for details see Supplements).
Xenograft Models and Tumor Implantation
All experiments were in accordance with international guide-
lines on the ethical use of animals and were approved by the
regional animal care committee (reg. number 02-069/11).
Throughout all procedures animals were anesthetized with
2.5% isoflurane (Aktavis, Langenfeld, Germany).
Subcutaneous tumors were induced on female athymic
nude mice (Hsd:Athymic Nude-Foxn1nu) (Harlan
Laboratories, Venray, The Netherlands). Hereto, 120 μl of
Matrigel™ (BD Biosciences, Bedford, USA) containing 2
million MDA-MB-231 cells (human breast adenocarcinoma,
doubling time in vitro: 1.8±0.5 days) or BxPC-3 cells (human
pancreatic adenocarcinoma, doubling time in vitro: 1.5±
0.3 days) (both ATCC,Wesel, Germany) were subcutaneously
implanted. The experiments were started once tumors
reached volumes between 80 and 500 mm3 as calculated by
the formula V = π/6 × (length × width × height of the tumor)
(20).
For each tumor model (breast and pancreatic tumors) four
independent animal groups were used. Group 1 received
magnetic hyperthermia treatments, which consisted in the
MNP intratumoral injection and the exposure to an
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alternating magnetic field (AMF, H=15.4 kA*m−1, f=
435 kHz) for 60 min. To investigate the impact of MNP alone
on tumor growth, group 2 received only MNP, but no AMF
treatment. Group 3 received ddH2O instead ofMNP and was
exposed to the AMF (H=15.4 kA*m−1, f=435 kHz) to inves-
tigate, if the AMF alone induced distinct effects on tumor
growth. To monitor the treatment independent tumor
growth, group 4 received only ddH2O.
Application of the Magnetic Material
The experimental workflow of the conducted in vivo magnetic
hyperthermia experiments can be seen in Fig. 1. On day -1
mice of group 1 and group 2 received MNP. The day after,
mice of group 1 and 3 were treated within the AMF. The
BxPC-3-xenograft bearing mice of group 1 and 2 were
injected intratumorally with 0.226 mg Fe per 100 mm3
(OD15:8.9 mg Fe/ml) or 0.087 mg Fe per 100 mm3
(MF66:4.3 mg Fe/ml). MDA-MB-231-xenograft bearing
mice received 0.535 mg Fe per 100 mm3 (OD15) or
0.24 mg Fe per 100 mm3 (MF66) via intratumoral infiltration.
Group 3 and 4 were injected using the same volume of
ddH2O like the volume of MNP (group 1 and 2). Magnetic
fluids and ddH2O were administered in a slow bolus into the
tumor center by a stepwise backtracking of the needle.
Injected volumes of MNP were chosen between 50 μl and
100 μl depending on the tumor entity.
Magnetic Hyperthermia Treatments
For AMF exposure, mice of group 1 (magnetic hyperthermia)
and group 3 (control, see above) were anaesthetized and
placed in a water-bathed half pipe (38°C) to stabilize the body
temperature during treatment. Tumors were selectively
treated for 60 min under given AMF conditions (H=
15.4 kA*m−1, f=435 kHz) (Fig. 1) and treatment was repeated
at 7 days thereafter. During magnetic hyperthermia, tumor
surface and rectal temperatures were monitored in situ using
fiber optic temperature sensors (TS5 & FOTEMPMK-19,
Optocon AG, Dresden, Germany). The tumor surface tem-
perature was additionally monitored in situ using an infrared
thermography camera (InfRec R300, Nippon Avionics Co.,
Ltd., Tokyo, Japan) during and 10 min pre- and post-
treatment.
Effects of Magnetic Hyperthermia on Tumor Volume
and Blood Count
Tumor volume (caliper) and body weight were measured
every 3 days (Fig. 1). The volume growth rate of untreated
tumors for both xenograft models was calculated as the in-
crease in tumor volume in percent per day related to the last
measurement. Then the arithmeticmean of the tumor volume
growth rates between all measurements was taken. On day -1,
14 and 28 after the initial treatment (Fig. 1), levels of red and
white blood cells and hemoglobin were measured via hema-
tology (Sysmex pocH-100i, Sysmex Deutschland GmbH,
Norderstedt, Germany).
Heat Maps
Heat maps (temperature distribution maps) of the treated
tumor region were extracted from the surface temperature
data recorded by infrared thermography. In this context
and using the thermal images (wavelengths between 8 and
14 μm) taken at 10, 30, and 50 min after switching on the
AMF, a polygonal region of interest (ROI, between 170
and 1,050 pixel) was placed over each tumor in a size
Fig. 1 Experimental workflow of in vivo magnetic hyperthermia experiments. One and seven days after magnetic nanoparticle (MNP) application, magnetic
hyperthermia was conducted on subcutaneous xenografts (AMF: H=15.5 kA*m−1, f=435 kHz) for 60 min. Tumor volume (Vtumor) and body weight (wtbody)
were monitored at the indicated days. Blood count of the animals was determined on day 0, 14 and 28 post first magnetic hyperthermia. AMF alternating
magnetic field.
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specific manner (see Supplementary information). The tem-
perature data of each pixel was extracted. T90 tempera-
tures and cumulative equivalent minutes at 43°C
(CEM43T90) were calculated according to Sapareto and
Dewey 1984 (4). Additionally, the contribution of different
tumor temperatures to the therapeutic effects was calculat-
ed more in detail. Accordingly, the temperature data were
grouped in three distinctive categories: proportion of
depicted tumor surface (in %) (I) with moderate hyperther-
mic temperatures (T<43°C, (6)), (II) hyperthermic temper-
atures (T 43–45°C), and (III) mild thermoablative temper-
atures (T>45°C). The relative contribution of each catego-
ry to the whole tumor surface temperature was calculated,
both AMF treatments (see Fig. 1) were summed up and
plotted against the relative tumor volume 28 days after the
initial magnetic hyperthermia.
Hematoxylin & Eosin Staining
Formalin-fixed and paraffin-embedded xenografts were sub-
jected to hematoxylin staining according to Mayer (Sigma-
Aldrich, Steinheim, Germany), followed by an 0.1% eosin B
staining (Sigma-Aldrich, Steinheim, Germany). After
washing in increasing concentrations of ethanol (50%,
70% and 96% (w/v)) and xylol, slides were covered with
Pertex® cover solution (PER 20000, medite GmbH, Burgdorf,
Germany).
Immunohistochemical KI-67 Staining
To assess the proliferative behavior of cells, magnetic hyper-
thermia treated (MF66) and untreated MDA-MB-231 tumor
tissue was extracted 2 days and 28 days after the first magnetic
hyperthermia treatment, with respect to the beginning
of the study. 3 μm paraffin embedded tumor sections
were stained for the presence of KI-67. Antigen retriev-
al was followed by a blocking step with avidin and
biotin and a primary monoclonal anti-KI-67 antibody
(Abcam, Cambridge, UK, 1:500 dilution) incubation
step. A polyclonal goat anti-rabbit IgG (H + L)-Biotin-
antibody (Dianova, Hamburg, Germany, 1:2,250 dilu-
tion) served as secondary antibody. For detection, a
streptavidin-AP conjugate (Southern Biotech, Birmingham,
USA, 1:75 dilution) and the REAL™ Detection System
Alkaline Phosphatase/RED (DAKO, Glostrup, DK) were
used. The slides were then stained with haematoxylin
(Sigma-Aldrich, Steinheim, Germany) and covered with
Faramount (DAKO, Glostrup, DK).
The evaluation of the stained slides was done by
three blinded observers. Therefore KI-67 positive areas
on whole tumor sections were viewed and grouped in
distinctive categories: (I) absent proliferation (0% KI-67
positive area), (II) mild proliferation (>0–25% KI-67
positive area), (III) moderate proliferation (>25–50% of
KI-67 positive area), (IV) high proliferation (>50–75%
KI-67 positive area) and (V) very high proliferation (>75%
KI-67 positive area).
Statistics
We assessed the significance of tumor volume differences in
the treatment groups by using the Mann–Whitney-U-Test
(SPSS 20.0). P-values of p≤0.05 and p≤0.01 were chosen to
be significant.
RESULTS
Magnetic Nanocrystal Synthesis and Characterization
MNP with average core size of 15±2 nm and 12±3 nm were
obtained by a decomposition method in organic media
(OD15) and via the co-precipitation route (MF66), respective-
ly. Both MNP formulations showed a narrow size distribution
(PDI: 0.14 for OD15, 0.12 for MF66) as it can be seen from
TEMmicrographs (Fig. 2a). Their hydrodynamic diameter in
water is smaller for OD15 in comparison toMF66 as shown in
Fig. 2b. Both MNP showed a comparable negative zeta
potenial of about −41 mV.
The exposure of MNP in a concentration of 2 mg Fe*ml−1
dispersed in water to the AMF (H=15.4 kA*m−1, f=435 kHz)
resulted in distinctly high SAR values (658±53 W*gFe
−1 for
OD15, 900±22 W*gFe
−1 for MF66). The minimization of
Brownian motion by immobilization in agarose gels resulted
in decreased SAR values (550±14 W*gFe
−1 (OD15) and 650
±31 W*gFe
−1 (MF66), Fig. 3a). Immobilization in
polyvinylalcohol hydrogels (PVA) led to an even stronger
decrease (382±39 W*gFe
−1 (OD15) and 520±46 W*gFe
−1
(MF66)). The conversion of the obtained SAR values into
intrinsic loss power (ILP) (Fig. 3a) led to values of 6.4±
0.5 nH*m2*kg−1 (OD15) and 8.7±0.2 nH*m2*kg−1 (MF66)
for MNP dispersed in water. Immobilization of nano-
particles in agar resulted in decreased ILP values: 5.3±
0.1 nH*m2*kg−1 for OD15 and 6.3±0.3 nH*m2*kg−1
for MF66. Immobilization in PVA led to ILP values of 3.7±
0.4 nH*m2*kg−1 for OD15 and 5.0±0.5 nH*m2*kg−1 for
MF66.
Further on we demonstrated that after incubation of cells
with OD15 or MF66, the MNP appeared in spots of high
density in a perinuclear localization (Fig. 3b), indicating their
cellular internalization. The localization of MNPs on the cell
surface or within intercellular spaces could be excluded
through thoroughly washing with HBSS. A comparable in-
tracellular uptake could be seen in tumor tissue 3 days after
intratumoral injection of MF66 into MDA-MB-231 tumors
(Fig. 3c).
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Therapeutic Effects of In VivoMagnetic Hyperthermia
Our analyses showed that intratumorally injected MNP re-
main during the whole experimental period within the tumor
site and are not transported to other organs (supplementary
Figure S1). These findings suggested the possibility of repeated
treatments of MNP bearing tumors (Fig. 1) in the AMF (H=
15.4 kA*m−1, f=435 kHz), which led to an evident reduction
Fig. 2 MNP characterization. (a) TEM micrographs and size distribution. Data was fitted to a lognormal distribution (red line). (b) MNP characteristics including
average core size, coating, hydrodynamic diameter (z-average), Polydispersity index (PDI) and zeta potential of OD15 and MF 66.MNPmagnetic nanoparticles.
Fig. 3 High SAR values for OD15 and MF66MNP dispersed in water, agarose and polyvinylalcohol. The two latest reproduce immobilization conditions in vivo.
(a) SAR values of both used MNP depending on the viscosity of the media (water, 1% (w/v) agar in water, 10% PVA in DMSO: water (80: 20% (v/v))). Intrinsic
loss power (ILP) of OD15 and MF66 dispersed in water, agarose, and PVA. (b) Prussian Blue staining of MDA-MB-231 cells after incubation with 125 pg Fe/cell of
OD15 and MF66 for 24 h at 37°C. Bars: 50 μm. (c) Hematoxylin stained tumor tissue of MF66 treated MDA-MB-231 xenografts 3 days after intratumoral
application. Nuclei stained blue, MNP stained brown. Bar: 20 μm. Error bars indicate standard deviations. MNP magnetic nanoparticles, PVA polyvinylalcohol
hydrogel, SAR specific absorption rate.
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of the tumor volume compared to untreated ones. Over a
time period of 4 weeks, breast MDA-MB-231 tumors showed
a significant shrinking of their relative volumes to 85%
(OD15, p≤0.05) and 50% (MF66, p≤0.01) in relation to the
tumor volumes before treatment. In contrast, untreated
MDA-MB-231 tumors showed linear growth over the same
time period, resulting in a relative tumor volume of 305% at
day 28 in comparison to day 0. Magnetic hyperthermia treat-
ed tumors had, compared to untreated ones, a volume of 27%
(OD15) and 17% (MF66), respectively (day 28 post first mag-
netic hyperthermia therapy, see Fig. 4a and Table I).
In pancreatic BxPC-3 xenografts, tumor growth was also
significantly reduced after magnetic hyperthermia. The relative
tumor volume at 28 days post first magnetic hyperthermia was
204% (OD15, p≤0.05), 244% (MF66, p≤0.05) compared to
507% of the untreated animal group. In relation to untreated
tumors, magnetic hyperthermia resulted in a tumor volume of
40–50% (OD15 andMF66) compared to untreated tumors (p≤
0.05, day 28 post first magnetic hyperthermia, Fig. 4b, Table I).
In MDA-MB-231 tumors the growth arrest (<100% of
initial tumor volume) persisted until 3 weeks after the second
therapy, whereas in BxPC-3-xenografts a regrowth 1 week
after the second magnetic hyperthermia was observed, which
was stronger in the outer regions or rims of the tumors. The
strongest volume increase took place in the last week between
day 20 and 28 post first magnetic hyperthermia (Fig. 4). In this
regard, in vitro thermal studies raising the temperature in the
incubator showed similar results, where MDA-MB-231 can-
cer cells were more sensitive to heat than BxPC-3 cells (sup-
plementary Figure S2).
During treatment, T90 temperatures (tumor surface tem-
perature which is exceeded by 90% of the tumor area, see
MATERIALS AND METHODS) were generally higher for
MF66 than in OD15 injected tumors (MDA-MB-231 xeno-
grafts: MF66: 41.2°C, OD15: 39.5°C; BxPC-3 xenografts:
MF66: 38.8°C OD15: 37.0°C, first magnetic hyperthermia,
Table I). Macroscopically, the thermal response was accompa-
nied by local changes on the tumor surface. The development
of eschars took place, followed by emarginations and tissue
loss. Due to the rather inhomogeneous MNP distribution after
intratumoral application a regrowth of tumor tissue (see above)
around former treated areas was observed between 14 and
28 days after first MNP or magnetic hyperthermia treatment.
Interestingly, successful tumor therapy was achieved with
comparatively low values of CEM43T90 (cumulative equivalent
minutes at 43°C, see MATERIALS AND METHODS). They
Fig. 4 Repeated treatment of MNP bearing tumors in the AMF (H=15.4 kA*m−1, f=435 kHz) led to significant reduction of tumor volume compared to
untreated ones. Effect of magnetic hyperthermia on the relative tumor volume in the course of a 4 week period after therapy in comparison to untreated tumors
for MDA-MB-231 (a) and BxPC-3 xenografts (b). Additionally T90 temperatures and macroscopic tumor images are displayed. (* p≤0.05, ** p≤0.01 (Mann–
Whitney-U-Test: treated vs. untreated)). Error bars indicate standard deviations. AMF alternating magnetic field, MNP magnetic nanoparticles, T90 temperature
exceeded by 90% of the tumor surface.
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ranged between 1.5 min (OD15) and 24.9 min (MF66) for
MDA-MB-231 and 1.9 min (OD15) and 1.0 min (MF66)
for BxPC-3 (Table I). However, we could show that, al-
though CEM43T90 values were below the hyperthermic
effective duration of 60 min, a distinct reduction of tumor
volumes still occurred. Heat map analysis revealed that
localized heat spots were present in the tumor region with
temperatures >43°C (Fig. 5). Magnetic hyperthermia with
MF66 MNP (Fig. 5a, c) induced an increased proportion of
high temperature areas (i.e. the categories II (T 43–45°C)
and III (T>45°C), see MATERIALS AND METHODS)
than OD15 MNP (Fig. 5b, d) (see also DISCUSSION).
Table I Parameters of Therapeutic Effects of In Vivo Magnetic Hyperthermia
MDA-MB-231 BxPC-3
OD15 MF66 OD15 MF66
Applied magnetic material [mg Fe/100 mm3] 0.535 0.240 0.226 0.087
T90 [°C] 1st MH 39.5±0.9 41.2±1.7 37.9±2.2 38.8±0.9
2nd MH 38.6±1.4 37.8±2.2 36.6±1.8 37.0±3.0
CEM43T90 [min] 1.5±1.3 24.9±30.2 1.9±4.0 1.0±1.0
Tumor volume growth rate 4.5±2.4%/day 4.5±2.4%/day 8.3±3.4%/day 8.3±3.4%/day
VT MH-28d/VT MH-0d 84.5±46.3% 49.8±29.2% 204±146% 244±124%
VT MH-28d/VT 28d 27.2% 16.6% 40.2% 48.1%
Applied magnetic materials, T90 temperatures, CEM43T90 values, tumor volume growth rates of untreated tumors and relative tumor volumes for OD15 and
MF66 in breast cancer (MDA-MB-231) and pancreatic cancer (BxPC-3) xenografts are shown. VT MH-28d/VT MH-0d : Quotient of mean tumor volume of magnetic
hyperthermia treated animals at day 28 and mean tumor volume of magnetic hyperthermia treated animals at day 0; VT MH-28d/VT 28d: Quotient of mean tumor
volume of magnetic hyperthermia treated animals at day 28 and mean tumor volume of untreated animals at day 28
CEM43T90 cumulative equivalent minutes at a T90 temperature of 43°C,MHmagnetic hyperthermia, T90 temperature exceeded by 90% of the tumor surface
Fig. 5 Despite the prevailing of tumor surface temperatures below 43°C, high temperature spots were also present. Temperature distributionmaps (heat maps)
of tumor surface temperatures of the two consecutive AMF treatments. The percentages of tumor area treated with temperatures below 43°C, between 43 and
45°C and above 45°C plotted against the individual relative tumor volume at 28 days after the first therapy are shown. MDA-MB-231 xenografts treated with
magnetic hyperthermia using MF66 (a) or OD15 (b). BxPC-3 xenografts treated with magnetic hyperthermia using MF66 (c) or OD15 (d). AMF alternating
magnetic field.
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Overall the hyperthermic spots were larger in MDA-MB-
231 than in BxPC-3 xenografts.
When tumors were treated with the AMF only (without
MNP injection), there was no intratumoral temperature in-
crease detectable (data not shown). The AMF treatment alone
led to tumor volumes strongly overlapping with untreated tu-
mors (Fig. 6). In this context, MDA-MB-231 xenografts tumors
had 177±123% of their starting volume (28 days after first
magnetic hyperthermia) compared to 305±126% of untreated
tumors (28 days after first magnetic hyperthermia). In BxPC-3
pancreatic cancer xenografts, AMF treated tumors had 396±
165% of their initial volume in contrast to untreated tumors
with 508±185% (28 days after first magnetic hyperthermia).
MNP injection alone (without application of an AMF)
showed a comparable growth of the tumors compared to
untreated ones. Tumors of the MDA-MB-231 xenograft
model elicited approximately 250% of their starting volume
(28 days after treatment), BxPC-3 xenografts nearly 490% of
their initial volume (28 days after treatment) for OD15 and
MF66, respectively.
Histological analysis of tumor sections of MDA-MB-231
xenografts at 2 days after the first magnetic hyperthermia
(MF66) treatment revealed distinct alterations of tumor cell
viability (Fig. 7). Magnetic hyperthermia induced extended
regions of apoptotic and necrotic tumor tissue (Fig. 7a), even
though vital areas were still present (Fig. 7b). Within the
apoptotic and necrotic areas, the nuclei were condensed and
fragmented, also cellular shrinkage took place. Between both
areas clearly distinguishable margins were observed (Fig. 7c,
dashed line). Untreated tumors consisted of viable, unaltered
tissue without strong signs of apoptosis or necrosis (Fig. 7d).
From the microscopical point of view, KI-67-staining was
visible in the remaining vital areas of the tumors (Fig. 8a).
Semi-quantitative examination of KI-67 staining as a marker
of proliferation of tumors has shown marked differences be-
tween the different treatment groups. MDA-MB-231 xeno-
grafts treated with magnetic hyperthermia revealed a reduced
proportion of areas with proliferating KI-67-positive cells at
2 days and 28 days after the first magnetic hyperthermia in
comparison to the non-treated animal group (Fig. 8a, b).
Assessing the biocompatibility of the treatment modality, the
sole intratumoralMNP injection, the exposure to the AMF only,
and the combination of both (magnetic hyperthermia) did not
result in any distinct changes of red and white blood cell count
and hemoglobin concentration. The observed values were within
the normal range values reported by a large provider of animal
research models (Fig. 9) (Harlan Laboratories, Venray, The
Netherlands; http://www.harlan.com). The body weight of the
animals was also not affected by the presence of the MNP and
the treatment in the AMF throughout the observation period of
28 days (supplementary Figure S3).
DISCUSSION
We have studied the magnetic heating effect of two types of
DMSA coated iron oxide nanoparticles with high SAR values
on breast and pancreatic cancer xenografts in athymic nude
mice. Hyperthermia treatment led to lethal temperatures
within the tumors and resulted in a pronounced reduction of
tumor volume compared to untreated tumors, with a stronger
response in the slower growing breast cancer tumors. We
carefully monitored the tumor surface temperature and were
able to assess heterogeneous temperature distributions. The
resulting temperature dosages of 1–24 CEM43T90 were low-
er than recommended in previous studies but showed great
treatment efficiency in our study. Both particle types were
biocompatible and did not affect the animal’s health without
hyperthermia treatment.
Heating Potential of the MNP
The MNP used in this study showed an exceptionally high
heating potential after suspension in water. The ILP values
Fig. 6 Neither the treatment within the alternating magnetic field (AMF, H=
15.4 kA*m−1, f=435 kHz), nor with the magnetic nanoparticles (MNP,
≤0.5 mg Fe per 100 mm3) alone had a significant effect on tumor growth
compared to the untreated animals. Relative tumor volume on day 28 of
MDA-MB-231 (a) and BxPC-3 xenografts (b) for animals after only AMF or
MNP treatment compared to untreated animals. Additionally, relative tumor
volumes of magnetic hyperthermia treated animals at 28 days after first
magnetic hyperthermia therapy for both xenograft models are displayed. (*
p≤0.05, ** p≤0.01 (Mann–Whitney-U-Test: treated vs. untreated)). Error
bars indicate standard deviations.
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obtained for the studiedMNP are among the highest values ever
reported on chemically synthesized iron oxide nanoparticles.
The intrinsic loss power of 6.4±0.5 nH*m2*kg−1 (OD15) and
8.7±0.2 nH*m2*kg−1 (MF66) of the MNP suspended in water
was more than twice as high as e.g. the values reported for 16
commercial superparamagnetic particles of comparable hydro-
dynamic sizes, which did not exceed 3.12 nH*m2*kg−1 (19).
Cervadoro et al. also extensively reviewed ILP values of MNP
available in the literature, mostly for frequencies around 500 kHz
and reported predominantly ILP values below 1 nH*m2*kg−1,
Fig. 7 Magnetic hyperthermia
leads to apoptosis and necrosis in
tumor tissue. Hematoxylin/eosin
stained tumor tissue of magnetic
hyperthermia (MF66) treated and
untreatedMDA-MB-231 xenografts
2 days after first magnetic
hyperthermia. (a) Necrotic and
apoptotic tissue, (b) Vital tumor
tissue, (c) Transition from necrotic
and apoptotic to vital tumor tissue
indicated by dashed line, (d) Vital
untreated tumor tissue. Tissue
sections were stained with
hematoxylin and eosin. Nuclei
stained blue, MNP stained brown.
Bars: 50 μm. MNP magnetic
nanoparticles.
Fig. 8 Magnetic hyperthermia
diminished proliferative activity of
tumor tissue compared to
untreated tissue. (a) KI-67 staining
of untreated and magnetic
hyperthermia (MF66) treated
MDA-MB-231 tumor tissue
extracted 2 days and 28 days after
the first magnetic hyperthermia. KI-
67 positive cells stained red, nuclei
stained blue. Bars: 200 μm. (b)
Percentage of KI-67 positive tissue
area 2 days and 28 days after the
respective treatment. Bars
represent categorical distribution of
KI-67 positive area within the whole
tissue section for all evaluated slides
per group. AMF alternating
magnetic field, MNP magnetic
nanoparticles.
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with some exceptions reaching ILP values between 4-
5 nH*m2*kg - 1 ( au tho r s r e f e r a s 4 , 000–5 , 000
10−12*W*m2*s*A−2*kg−1) (21). This underlines that the heating
potenial of theMNP in this work readily exceeded those reported
for most conventional MNP (22). Expressing SAR values as ILP
is a physical magnitude for comparing heating efficiencies ob-
tained under different HAC conditions (19). The conversion of
SAR into ILP values has proper sense only within the limits
of the linear response theory where the magnetic response
of MNP is linear with the applied magnetic field (i.e. when
the maximum applied field amplitude is much smaller than
magnetic field at which magnetization saturates) (23).
Analysis of saturation magnetization of OD15 and
MF66 at room temperature under quasi-static conditions
resulted in field amplitude values of around 400 kA*m−1,
which are approximately 20 times larger than the AMF
amplitude employed in this study. Under AMF conditions
at 435 kHz, the field amplitudes at which magnetization
saturates are probably even larger. Therefore the AMF
conditions employed in this work met the requirements
for the conversion of SAR into ILP values.
Regarding the SAR and ILP data both synthetized formu-
lations are suitable candidates for applications in magnetic
hyperthermia.
The use of ILP would be desirable in future studies for
establishing a heating efficiency parameter independent of
AMF conditions. SAR values cannot be compared directly
since it tightly depends on the field frequency and amplitude
employed. On the other hand, when comparing the SAR
values of the studied MNP in this work with others, their
stronger heat release becomes apparent. OD15 and MF66
show SAR values in water between 658 and 900 W*gFe
−1
(H=15.5 kA*m−1, f=435 kHz) which are higher in compar-
ison to values of 471 W*gFe
−1 reported by Yu et al. 2012 for
15 nm Zn0.4Fe2.6O4 MNP in more extreme AMF condi-
tions (H=37.4 kA*m−1, f=500 kHz) (24). Other studies
which applied similar AMF conditions (H=11 kA*m−1,
f=411 kHz) to ours on MNP between 15 and 18 nm
core size reported SAR values in the order of 500 W*gFe
−1
(25,26).
However, the heating potential of MNP dispersed in water
can be different to the treatment situation in living tissue,
because MNP were found to be immobilized to membranes
or in intracellular vesicles (27,28). We showed that after im-
mobilization, where one of the heating mechanims—
Brownian motion—is inhibited, ILP values were still higher
than those for water nanoparticle dispersions as reported by
Kallumadil et al. 2009 (19).
The differences in particle size and size distribution,
although small, led to differences in heating potential of the
MNP, where the MF66 MNP showed a higher SAR than
OD15 MNP.
The exceptionally high SAR and ILP values for the studied
MNP are related to distinct reasons. On one hand, the
Fig. 9 OD15 andMF66magnetic hyperthermia treatment did not alter the blood composition, indicating a good biotolerability. The number of white blood cells
(*103*μl−1), red blood cells (*106*μl−1), and the amount of hemoglobin (g*dl−1) are displayed for the magnetic hyperthermia treatment and the three control
groups at 0 day, 14 days and 28 days after first hyperthermia. Black dashed lines refer to reference values (Harlan Laboratories, Venray, The Netherlands; http://
www.harlan.com). MDA-MB-231 xenografts treated with MF66 (a) or OD15 (b). BxPC-3 xenografts treated with MF66 (c) or OD15 (d). Error bars indicate
standard deviations. AMF alternating magnetic field, MNP magnetic nanoparticles.
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chemical route of OD15 particles was optimized to obtain
monodisperse nanoparticles exhibiting optimal magnetic
properties and high SAR values (14). On the other hand,
MF66 were synthesized by co-precipitation route resulting in
non-uniform size and morphology MNP (Fig. 2a). Thus, the
heating efficiency of MF66 may profit from the larger MNP
size contribution and also from the elongated shape leading to
higher anisotropy values, and therefore, higher SAR values
(29).
After artificial immobilization, the SAR values of MF66
MNP were still higher than for OD15 MNP, supporting that
their heating depended less on Brownian motion than OD15
MNP. Therefore the importance of Neél relaxation as
predominating heating mechanism for theMNP is underlined
(30). In this regard, particularly MF66 MNP are favorable for
in vivo applications for controlling the heat exposure.
Therapeutic Effects of In VivoMagnetic Hyperthermia
We could show that magnetic particle induced hyperthermia
significantly reduced (MDA-MB-231) or inhibited (BxPC-3)
tumor growth compared to untreated tumors. Successful
magnetic hyperthermia could already be achieved by 1–2
CEM43T90, although a higher temperature dose led to
further decrease of the tumor volume. Nevertheless, a
comparison of these values to the existing literature is
challenging, because of the variety of methods used to
deliver hyperthermia and to monitor thermal dose and due
to the fact that most groups have been treating the tumors not
only with hyperthermia but also with radiotherapy.
However, to the best of our knowledge, the CEM43T90
temperatures needed to achieve these effects were lower than
ever reported in the literature. A number of studies which
report CEM43T90 temperatures fail to find a correlation
between thermal dosage of above 10 CEM43T90 and tumor
response (8,9), whereas other studies, which compared low
temperature doses (lower than 5 CEM43T90) with high ones
(10–100 CEM43T90) reported low therapy response for par-
ticularly the low dose hyperthermia (12,13).
Presumably, the observed high efficiency of comparatively
low CEM43T90 is, at least in part, caused by the nature of
MNP induced hyperthermia, which was reported to be more
cytotoxic to tumor cells than hot water hyperthermia (31,32).
The underlying reasons can be found in the occurrence of
hyperthermic spots, which we were able to identify by infrared
thermography. This refers to very localized areas of the
tumors that reached temperatures between 43 and 45°C
(hyperthermic temperatures) and above 45°C (mild
thermoablative temperatures). Emanating from these spots,
intratumoral temperature gradients might well lead to cell
death up to a defined distance from the magnetic material.
These heating spots are the result of the intratumoral distri-
bution pattern of the magnetic material.
It is worth mentioning that the calculation of T90 and
CEM43T90 values was performed using data inferred from
tumor surface temperatures (supplementary Figure S4).
Taking into account that non-invasive thermometry is not
available at the present, we were able to show that the tem-
peratures inside the tumor were even higher (0.1–0.2°C) than
temperatures measured at the tumor surface (supplementary
Figure S5) for a BxPC-3 xenograft injected with MNP and
treated within the AMF. The acquisition of the temperature
data used in this study was suitable to address the specific
questions, however T90 and CEM43T90 values within the
tumor region could be slightly higher than the ones obtained
at the tumor surface.
Obviously, even though mostly of heterogeneous nature,
the intratumoral deposition of magnetic material is highly
efficient as our results show (33,34). The accumulation of
nanoparticles in sufficient amounts in tumor tissue after sys-
temic (intravenous) application is a yet unsolved challenge in
magnetic hyperthermia research (21,35). Until the major
challenges such as the nanoparticle removal from the blood
stream and an enhanced tumor uptake and retention are
resolved, intratumoral injection is the best method to reach
a sufficient amount of nanoparticles at the tumor site to induce
heating (35,36). Furthermore, intratumoral application of
magnetic material is readily applicable in the clinical setting
using stereotactical methods in radiology, where the magnetic
material can e.g. be applied during a biopsy process under
visual guidance.
A distinct reduction of the tumor volumes was observed,
even though tumors did not disappear completely after mag-
netic hyperthermia therapy. Interestingly, it has been shown
that less aggressive therapeutic approaches can be beneficial
for tumor regression compared to more radical approaches
leading to hypoxic areas by destroying tumor vasculature (37).
Hypoxia is known to select for more malignant cells with
increased metastatic potential (38). It remains to be elucidated
how the corresponding intratumoral particle distribution pat-
terns can cover the whole target area with adequate temper-
ature dosages in order to get the tumor growth under control.
Magnetic hyperthermia effects in both tumor models were
provoked by a smaller amount of MF66 MNP than OD15
MNP. Since MF66 MNP had a higher ILP than OD15, and,
in consequence, smaller amounts are required at the tumor,
we conclude that ILP of the magnetic material has a higher
impact on therapy outcome than the amount of magnetic
material applied to the tumor. In perspective of systemic
applications small MNP amounts at the tumor site is desirable
for hyperthermia treatment, since delivery to the tumor is,
despite of possible nanoparticle functionalizations with target-
affine ligands, unalterably coupled to the extent of the en-
hanced permeability and retention effect (EPR effect) (35,39).
Independently of the MNP type (MF66 or OD15), the
applied MNP amount or the temperature dosage used for
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magnetic hyperthermia, the therapeutic effects were cell line
dependent in a wide sense. For example, MDA-MB-231
tumors treated with OD15 received a temperature dosage
intermediate between OD15 treated BxPC-3 and MF66
treated BxPC-3, while the amount of applied magnetic mate-
rial was higher for MDA-MB-231 xenografts. The different
dosages were the result of the varying interstitial pressure
between these tumors (lower values for MDA-MB-
231compared to BxPC-3, own observations). However, tu-
mor volume ofMDA-MB-231 tumors was distinctly smaller at
the end of the experiment than that of BxPC-3 tumors.
Whether this difference was caused by a higher proliferation
rate of BxPC-3 cells (BxPC-3 doubling time in vitro: 1.5±0.5
days vs. 1.8±0.5 days for MDA-MB-231) or by differences in
thermotolerance between the two cell lines and/or by the
effect of tumor interstitial pressure on magnetic material dos-
ing will be the subject of further in depth investigations. First
in vitro thermal studies indicated that MDA-MB-231 are more
sensitive to heat than BxPC-3 cells and are therefore more
effectively inactivated by hyperthermia treatment (supplemen-
tary Figure S2), which is in line with our in vivo observations.
Comparing the first and second hyperthermia treatment it is
noticeable that T90 temperatures are always lower during the
second therapy. The reason for this observation is primarily
not in MNP degradation, but rather the massive tissue
remodeling which takes place after the first treatment
leading to MNP redistribution. Previous works (40) have
shown that the heating potential of MNPs after intratumoral
application is not altered for several days and therefore the
heating efficiency is not influenced. The appearance of eschars
and disintegration of dead tissue results in dense intratumoral
MNP clusters leading to high temperature spots. In order to
not excess the hyperthermic temperature, AMF power often
had to be reduced during the second treatment, leading to an
overall lower temperature dose.
Importantly, we could demonstrate each magnetic hyper-
thermia component alone, either AMF orMNP exposure, did
not lead to significant effects on tumor volume, underlining
that the therapeutic effects depended merely on the combina-
tion of both the MNP and the AMF treatment (and the
hyperthermic temperatures induced by the magnetic hyper-
thermia). Hence, nanoparticle application without AMF does
not transmit cytotoxic effects and neither does AMF exposure
when no magnetic material is present.
As shown for the MDA-MB-231 xenograft model, tumor
volume of the magnetic hyperthermia group stagnated in the
course of the long term observation during 28 days, whereas
the untreated control group showed continued linear tumor
growth. These observations were in accordance with the KI-
67 expression pattern that predominantly showed KI-67 ex-
pression in 0 to 25% of tumor area after the first AMF
treatment and at the end of the experimental period on day
28. The untreated and MNP only group on the other side,
showed an increase in KI-67 expression from day 2 to day 28
with KI-67 expression in larger areas of the tumors. Hence,
magnetic hyperthermia depleted the proliferative activity of
treated tumors, which was macroscopically observed as tumor
volume reduction and growth stagnation. Furthermore, the
low proliferative activity even 21 days after the last magnetic
hyperthermia leads us to the conclusion that, in this case,
tumor volume is unlikely to strongly increase over time.
In the view of further investigations towards clinical studies
involving theMNP used in the present study, it is important to
announce that they showed excellent biocompatibility.
Animals showed no affection throughout the experiments
and we observed no pathological change in the white and
red blood cells and hemoglobin levels. Body weight of the
animals was also not affected (supplementary Figure S3).
In the future, a systemic application instead intratumoral
MNP application would be desirable to be able to treat deep
seated tumors and metastases. Importantly it has to be kept in
mind that by functionalizing nanoparticles with targeted
molecules only the uptake into tumor or endothelial cells
can be improved, whereas the delivery of MNP from the
vascular system into the tumor interstitium depends solely
on the EPR effect, independently of the nanoparticle
functionalization (35). In contrast, after intratumoral applica-
tion defined amounts of iron is deposited, which generally
remain at the tumor site, making hyperthermia treatment
much more projectable and predictable.
CONCLUSION
In conclusion, magnetic hyperthermia using iron oxide nano-
particles with exceptionally high ILP lead to an effective
tumor growth reduction or delay in subcutaneous xenografts
although measured CEM43T90 temperatures were lower
than recommended in the literature. Both nanoparticle for-
mulations were adequate for in vivo hyperthermia experi-
ments, but MF66 (aqueous synthesis route) displayed a higher
heating potential and led to higher T90 values than OD15
(organic synthesis route). The better response of breast cancer
xenografts to the therapy compared to pancreatic tumors is
the result of multifactorial reasons and will be subject of
further investigations. Furthermore the excellent biocompati-
bility of theMNP and localized therapymade the therapy well
tolerable for the animals.
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